美康生物
(300439)
| 流通市值：25.73亿 | | | 总市值：33.82亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 376,022,696.88 | 1,539,159,714.69 | 1,135,669,290.81 | 736,221,523.12 |
| 营业总成本 | 351,135,278.16 | 1,516,898,858.66 | 1,105,821,644.63 | 706,593,829.78 |
| 其他经营收益 | | | | |
| 营业利润 | 37,610,621.62 | 33,265,221.82 | 54,101,653.44 | 54,601,857.18 |
| 利润总额 | 36,976,398.24 | 46,092,646.26 | 53,406,580.01 | 56,943,972.96 |
| 净利润 | 33,187,998.12 | 61,361,976.78 | 58,893,569.05 | 55,608,076.33 |
| 每股收益 | | | | |
| 其他综合收益 | 737,416.79 | -628,731.08 | 1,261,533.54 | 1,302,862.97 |
| 综合收益总额 | 33,925,414.91 | 60,733,245.7 | 60,155,102.59 | 56,910,939.3 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,846,407,238.12 | 1,892,669,565.76 | 1,879,895,641.43 | 1,857,744,984.16 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,747,660,205.42 | 1,761,028,620.2 | 1,775,350,820.43 | 1,797,528,836.64 |
| 资产总计 | 3,594,067,443.54 | 3,653,698,185.96 | 3,655,246,461.86 | 3,655,273,820.8 |
| 流动负债: | | | | |
| 流动负债合计 | 534,005,769.7 | 623,985,598.16 | 602,922,198.57 | 604,777,563.3 |
| 非流动负债: | | | | |
| 非流动负债合计 | 78,902,660.27 | 82,078,989.14 | 103,836,229.57 | 105,252,387.07 |
| 负债合计 | 612,908,429.97 | 706,064,587.3 | 706,758,428.14 | 710,029,950.37 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,987,596,254.16 | 2,954,214,677.08 | 2,955,784,542.29 | 2,952,110,239.82 |
| 股东权益合计 | 2,981,159,013.57 | 2,947,633,598.66 | 2,948,488,033.72 | 2,945,243,870.43 |
| 负债和股东权益合计 | 3,594,067,443.54 | 3,653,698,185.96 | 3,655,246,461.86 | 3,655,273,820.8 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 401,149,719.09 | 1,567,591,925.06 | 1,395,144,984.04 | 940,356,825.33 |
| 经营活动现金流出小计 | 458,973,970.43 | 1,300,977,014.11 | 1,250,167,239.09 | 844,070,909.74 |
| 经营活动产生的现金流量净额 | -57,824,251.34 | 266,614,910.95 | 144,977,744.95 | 96,285,915.59 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 206,169,213.63 | 1,000,054,373.16 | 723,164,208.45 | 535,787,089.08 |
| 投资活动现金流出小计 | 213,945,535.89 | 1,258,407,877.19 | 873,382,080.85 | 604,682,628.27 |
| 投资活动产生的现金流量净额 | -7,776,322.26 | -258,353,504.03 | -150,217,872.4 | -68,895,539.19 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 37,538,668.06 | 2,694,000 | 2,694,000 |
| 筹资活动现金流出小计 | 20,085,510.47 | 114,251,446.15 | 93,191,945.04 | 68,733,899.72 |
| 筹资活动产生的现金流量净额 | -20,085,510.47 | -76,712,778.09 | -90,497,945.04 | -66,039,899.72 |
| 汇率变动对现金及现金等价物的影响 | -203,657.26 | -725,233.89 | -487,295.89 | -390,807.3 |
| 现金及现金等价物净增加额 | -85,889,741.33 | -69,176,605.06 | -96,225,368.38 | -39,040,330.62 |
| 期末现金及现金等价物余额 | 571,548,689.96 | 657,438,431.29 | 630,389,667.97 | 687,574,705.73 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -69,176,605.06 | - | -39,040,330.62 |